SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) have announced the inauguration of joint laboratories dedicated to advancing cellular immunotherapies. With close to S$30 million in combined funding under Singapore’s Research, Innovation and Enterprise 2025 Plan (RIE2025), this collaboration aims to propel the development of induced pluripotent stem cell (iPSC) technology towards producing innovative cell therapies meeting stringent Good Manufacturing Practice (GMP) standards.

SCG细胞疗法（SCG）和科学、技术和研究机构（A*STAR）宣布成立致力于推进细胞免疫疗法的联合实验室。根据新加坡研究、创新和企业2025计划（RIE2025），这项合作的联合资金接近3000万新元，旨在推动诱导多能干细胞（iPSC）技术的发展，以生产符合严格良好生产规范（GMP）标准的创新细胞疗法。

Additionally, the partnership will establish a talent development program geared towards nurturing the next generation of experts in this domain, aligned with prevailing GMP and regulatory requisites.The pursuit of novel technologies is indispensable in addressing evolving healthcare demands and ensuring sustained viability.

此外，该合作伙伴关系将建立一个人才发展计划，旨在培养该领域的下一代专家，符合现行GMP和监管要求。追求新技术对于满足不断变化的医疗保健需求和确保持续生存能力至关重要。

Nevertheless, translating laboratory breakthroughs into pragmatic clinical solutions presents formidable hurdles. These challenges often involve devising manufacturing protocols, validating analytical methodologies, and integrating automation and digitalization to assure product stability and scalability.The joint laboratories, situated within SCG’s GMP facility and ASTAR’s research center, capitalize on SCG’s and ASTAR’s proprietary technologies to develop scalable GMP-grade iPSC and therapeutic products.

然而，将实验室突破转化为实用的临床解决方案存在着巨大的障碍。这些挑战通常涉及设计制造协议，验证分析方法，以及集成自动化和数字化以确保产品的稳定性和可扩展性。联合实验室位于SCG的GMP设施和ASTAR的研究中心内，利用SCG和ASTAR的专有技术开发可扩展的GMP级iPSC和治疗产品。

SCG brings to the table its specialized automated cell therapy manufacturing technologies, while A*STAR contributes its distinctive monoclonal antibody assets, iPSC banks, and proficiency in process scaling and analytics.This collaboration serves as a conduit between public sector research and development (R&D) and industry, pooling resources from SCG Cell Therapy and A*STAR’s Bioprocessing Technology Institute (BTI) and Institute of Molecu.

SCG将其专业的自动化细胞治疗制造技术带到了桌面上，而A*STAR则贡献了其独特的单克隆抗体资产，iPSC库以及在过程缩放和分析方面的熟练程度。这种合作是公共部门研究与开发（R＆D）与工业之间的渠道，汇集了SCG细胞疗法和a*STAR生物加工技术研究所（BTI）和Molecu研究所的资源。